EML4 and adenocarcinoma: Aberrant ALK fusion gene is identified in 3 to 7% of NSCLC cases, mostly in adenocarcinoma, and the most common fusion is with the echinoderm microtubule-associated protein-like 4 (EML4) [2–5].